Company Performance Metrics
ValThera develops medical devices for the minimally invasive treatment of structural heart disease, with a focus on tricuspid valve regurgitation. The company designs a transcatheter tricuspid valve replacement system intended for percutaneous implantation. Its technology combines advanced cardiac device engineering with clinical and imaging
expertise to create a physiologically oriented solution for tricuspid valve disease. The system features a proprietary anchoring mechanism to enable precise steering and positioning of a prosthetic valve within the tricuspid orifice. The prosthetic valve design is configured to interact with native tissue and the annulus in a way that minimizes residual regurgitation, thrombus formation, and disruption of surrounding structures. ValThera targets patients for whom conventional surgical options are limited and seeks to enable catheter-based treatment of significant tricuspid regurgitation.
